When tafasitamab (Monjuvi, Incyte), an anti-CD19 monoclonal antibody, is added to a regimen that includes the anti-CD20 monoclonal antibody rituximab, patients with follicular lymphoma (FL) do substantially better, according to the results of a multinational phase 3 trial.
The addition of tafasitamab to a combination of rituximab and lenalidomide is relatively well tolerated and “can be administered in a community as well as academic settings, and represents a potential new standard of